Amylin Symlin Study Will Evaluate Hypoglycemia Risk During Dose Initiation

Amylin is planning a six-week Symlin safety study to evaluate the increased incidence of hypoglycemia associated with the antidiabetic agent, the company said following a July 26 FDA advisory committee recommendation against approval of the drug.